Polypid Ltd is a biotechnology company focused on developing innovative therapeutic products for surgical procedures
The company harnesses its proprietary polymer technology to create drug-delivery systems that aim to improve patient outcomes by minimizing the risk of infections and enhancing the healing process. Polypid's flagship products are designed to be applied directly at the surgical site, providing controlled release of medications over an extended period. Through its research and development efforts, Polypid seeks to address unmet medical needs in the surgical landscape while promoting safe and effective treatment options for patients.
NEW YORK, NY / ACCESS Newswire / March 18, 2025 / The Investor Summit is excited to announce that presentations from Q1 Investor Summit are now available for on-demand viewing. Attendees and investors who missed the live sessions can now access company presentations at their convenience.
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / The Investor Summit Group (ISG), today announced that Ori Warshavsky, Chief Operating Officer - US Operations and Jonny Missulawin, Chief Financial Officer of PolyPid Ltd. (Nasdaq:PYPD), a late-stage biopharma company aiming to improve surgical outcomes will be presenting at this year's Investor Summit Virtual Conference on March 11th, 2025.
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earnings at $1.65 per share on revenue of $24.62 billion.
Gainers Inpixon (NASDAQ: INPX) shares rose 41% to $2.20 in pre-market trading after gaining 6% on Tuesday. Inpixon, last month, secured a purchase order valued at over $1m for its RTLS products from a leading transportation and industrial equipment provider.
Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares surged 85% to $2.2200. Sonoma Pharmaceuticals and EMC Pharma announced Department of Defense DAPA registration for Microcyn(R) Rx products.
